Cancer Clinical Trial Eligibility Criteria: Performance Status
Guidance for Industry, IRBs, and Clinical Investigators
Guidance for Industry, IRBs, and Clinical Investigators
PURPOSE Taletrectinib, a highly potent, CNS-active, ROS1 tyrosine kinase inhibitor (TKI), has demonstrated high and durable response rates, high intracranial objective response rate (ORR), prolonged…
PURPOSE Previous comparative effectiveness studies have not demonstrated a benefit of proton beam therapy (PBT) compared with intensity-modulated radiation therapy (IMRT) for prostate cancer. An…
The Lancet Commission on Women, Power, and Cancer was created to address the overlapping forms of discrimination that women face in cancer prevention and treatment…
Safety of administration of a vindesine (VDS)-anti-CEA conjugate and its ability to localise after radiolabelling were investigated in patients with advanced metastatic carcinoma (4 colorectal…
Review of available evidence related to treatment decisions. Signposting to other important services such as therapy, psychosexual counselling, and fertility preservation. You will also have…
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend. Jetzt gleich den Fragebogen ausfüllen! Durch…
We would like to invite ENGAGe members and supporters to the webinar on endometrial cancer prevention. The webinar is organised in cooperation with ESGO Prevention…
On May 30, 2024, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with relapsed or refractory mantle cell…
PURPOSE Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, ALK-positive non–small cell lung cancer (NSCLC) in the…